Symbols / MNKD Stock $3.52 -0.85% MannKind Corporation

Healthcare • Biotechnology • United States • NGM
MNKD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Michael E. Castagna Pharm.D.
Exch · Country NGM · United States
Market Cap 1.09B
Enterprise Value 1.39B
Income -23.91M
Sales 360.78M
FCF (ttm) 47.00M
Book/sh -0.17
Cash/sh 0.43
Employees 591
Insider 10d —
IPO Jul 28, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 143.00
Forward P/E 18.29
PEG 4.39
P/S 3.01
P/B -21.20
P/C —
EV/EBITDA 39.29
EV/Sales 3.85
Quick Ratio 1.43
Current Ratio 1.87
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.07
EPS next Y 0.19
EPS Growth —
Revenue Growth 15.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA 2.03%
ROE —
ROIC —
Gross Margin 75.63%
Oper. Margin -3.31%
Profit Margin -6.63%
Shs Outstand 308.95M
Shs Float 303.27M
Insider Own 1.56%
Instit Own 62.36%
Short Float 9.71%
Short Ratio 5.38
Short Interest 29.58M
52W High 6.51
vs 52W High -45.93%
52W Low 2.23
vs 52W Low 57.85%
Beta 1.04
Impl. Vol. 2.60%
Rel Volume 1.46
Avg Volume 6.46M
Volume 9.45M
Target (mean) $7.22
Tgt Median $7.00
Tgt Low $4.75
Tgt High $10.00
# Analysts 8
Recom Strong_buy
Prev Close $3.55
Price $3.52
Change -0.85%
About

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.22
Mean price target
2. Current target
$3.52
Latest analyst target
3. DCF / Fair value
$2.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.52
Low
$4.75
High
$10.00
Mean
$7.22

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main RBC Capital Sector Perform → Sector Perform $5
2026-05-07 main Wells Fargo Overweight → Overweight $10
2026-05-07 main Mizuho Outperform → Outperform $7
2026-05-07 main HC Wainwright & Co. Buy → Buy $10
2026-04-28 main Wells Fargo Overweight → Overweight $8
2026-04-13 main Mizuho Outperform → Outperform $8
2026-03-05 main Wedbush Outperform → Outperform $8
2026-02-27 down RBC Capital Outperform → Sector Perform $4
2026-02-27 main Wells Fargo Overweight → Overweight $7
2026-02-27 main HC Wainwright & Co. Buy → Buy $8
2026-02-25 reit HC Wainwright & Co. Buy → Buy $11
2026-01-26 reit HC Wainwright & Co. Buy → Buy $11
2025-11-24 init Truist Securities — → Buy $9
2025-11-11 main RBC Capital Outperform → Outperform $8
2025-11-11 main Wells Fargo Overweight → Overweight $8
2025-10-13 reit HC Wainwright & Co. Buy → Buy $11
2025-09-18 reit HC Wainwright & Co. Buy → Buy $11
2025-09-05 main Oppenheimer Outperform → Outperform $15
2025-09-03 main Wells Fargo Overweight → Overweight $10
2025-09-02 main HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest MNKD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 CASTAGNA MICHAEL E Chief Executive Officer — 100,000 $2.59 $259,000
2026-02-27 HOOPER ANTHONY C Director — 35,000 $3.27 $114,450
2026-02-27 SHANNON JAMES SAMUEL Director — 12,000 $3.27 $39,240
2026-02-27 TROSS STUART A Officer — 15,290 $3.27 $49,998
2026-02-27 CASTAGNA MICHAEL E Chief Executive Officer — 15,290 $3.27 $49,998
2026-02-27 PRENTISS CHRISTOPHER B. Chief Financial Officer — 5,000 $3.27 $16,350
2026-01-08 TROSS STUART A Officer — 47,006 $6.33 $297,548
2025-12-24 CASTAGNA MICHAEL E Chief Executive Officer — 44,171 $0.00 $0
2025-12-17 CASTAGNA MICHAEL E Chief Executive Officer — 65,804 $6.01 $395,482
2025-12-17 CASTAGNA MICHAEL E Chief Executive Officer — 65,804 $4.55 $299,408
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
348.97
+22.23%
285.50
+43.50%
198.96
+99.42%
99.77
Operating Revenue
402.92
+18.75%
339.30
+32.85%
255.39
+155.98%
99.77
Cost Of Revenue
87.96
+14.83%
76.60
+22.03%
62.77
+9.17%
57.50
Reconciled Cost Of Revenue
79.65
+15.05%
69.23
+18.88%
58.24
+1.29%
57.50
Gross Profit
261.01
+24.94%
208.90
+53.39%
136.19
+222.17%
42.27
Operating Expense
214.46
+52.94%
140.22
+11.64%
125.60
+12.95%
111.19
Research And Development
66.35
+44.57%
45.89
+46.70%
31.28
+58.63%
19.72
Selling General And Administration
144.13
+52.80%
94.33
+0.02%
94.31
+3.11%
91.47
Selling And Marketing Expense
—
—
51.78
-3.68%
53.75
General And Administrative Expense
—
—
42.54
+12.77%
37.72
Other Gand A
—
—
42.54
+12.77%
37.72
Other Operating Expenses
—
—
—
—
Total Expenses
302.42
+39.48%
216.82
+15.11%
188.37
+11.66%
168.69
Operating Income
46.55
-32.22%
68.68
+548.29%
10.59
+115.37%
-68.92
Total Operating Income As Reported
38.80
-46.55%
72.59
+736.45%
8.68
+113.54%
-64.11
EBITDA
51.51
-31.92%
75.66
+295.90%
19.11
+133.93%
-56.32
Normalized EBITDA
65.67
-25.79%
88.49
+317.46%
21.20
+135.21%
-60.20
Reconciled Depreciation
12.28
+66.65%
7.37
+62.54%
4.54
-28.15%
6.31
EBIT
39.23
-42.56%
68.29
+368.51%
14.58
+123.27%
-62.63
Total Unusual Items
-14.16
-10.37%
-12.83
-514.96%
-2.09
-153.78%
3.88
Total Unusual Items Excluding Goodwill
-14.16
-10.37%
-12.83
-514.96%
-2.09
-153.78%
3.88
Special Income Charges
-6.41
+61.70%
-16.73
-9744.12%
-0.17
0.00
Other Special Charges
—
20.44
—
—
Impairment Of Capital Assets
—
—
—
0.00
Restructuring And Mergern Acquisition
0.00
+100.00%
-5.26
0.00
0.00
Write Off
6.41
+313.48%
1.55
+811.76%
0.17
0.00
Net Income
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Pretax Income
1.41
-95.39%
30.52
+394.09%
-10.38
+88.13%
-87.40
Net Non Operating Interest Income Expense
-29.98
-18.17%
-25.37
-33.46%
-19.01
+14.60%
-22.26
Interest Expense Non Operating
37.82
+0.13%
37.77
+51.37%
24.95
+0.74%
24.77
Net Interest Income
-29.98
-18.17%
-25.37
-33.46%
-19.01
+14.60%
-22.26
Interest Expense
37.82
+0.13%
37.77
+51.37%
24.95
+0.74%
24.77
Interest Income Non Operating
8.05
-36.16%
12.62
+104.99%
6.15
+144.89%
2.51
Interest Income
8.05
-36.16%
12.62
+104.99%
6.15
+144.89%
2.51
Other Income Expense
-15.17
-18.53%
-12.80
-551.53%
-1.96
-152.00%
3.78
Other Non Operating Income Expenses
-1.01
-3253.13%
0.03
-73.77%
0.12
+219.61%
-0.10
Gain On Sale Of Security
-7.75
-298.34%
3.91
+303.91%
-1.92
-149.39%
3.88
Tax Provision
-4.46
-252.08%
2.93
+87.70%
1.56
0.00
Tax Rate For Calcs
0.00
+118.75%
0.00
-54.29%
0.00
0.00
Tax Effect Of Unusual Items
-2.97
-141.43%
-1.23
-181.12%
-0.44
0.00
Net Income Including Noncontrolling Interests
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Net Income From Continuing Operation Net Minority Interest
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Net Income From Continuing And Discontinued Operation
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Net Income Continuous Operations
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Normalized Income
17.05
-56.49%
39.18
+480.80%
-10.29
+88.73%
-91.28
Net Income Common Stockholders
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Diluted EPS
0.02
-80.00%
0.10
+350.00%
-0.04
+88.24%
-0.34
Basic EPS
0.02
-80.00%
0.10
+350.00%
-0.04
+88.24%
-0.34
Basic Average Shares
305.64
+11.38%
274.42
+2.77%
267.01
+3.86%
257.09
Diluted Average Shares
314.11
+10.66%
283.84
+6.30%
267.01
+3.86%
257.09
Diluted NI Availto Com Stockholders
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Amortization
3.97
0.00
0.00
—
Amortization Of Intangibles Income Statement
3.97
0.00
0.00
—
Depreciation Amortization Depletion Income Statement
3.97
0.00
0.00
—
Depreciation And Amortization In Income Statement
3.97
0.00
0.00
—
Total Other Finance Cost
0.21
-0.96%
0.21
+0.48%
0.21
—
Line Item Trend 2023-12-31
Total Assets
475.20
Current Assets
373.39
Cash Cash Equivalents And Short Term Investments
295.10
Cash And Cash Equivalents
238.48
Cash Financial
—
Other Short Term Investments
56.62
Receivables
14.90
Accounts Receivable
14.90
Gross Accounts Receivable
23.74
Allowance For Doubtful Accounts Receivable
-8.84
Inventory
28.55
Raw Materials
6.26
Work In Process
13.65
Finished Goods
8.64
Prepaid Assets
—
Restricted Cash
—
Other Current Assets
34.85
Total Non Current Assets
101.81
Net PPE
84.22
Gross PPE
185.76
Accumulated Depreciation
-101.54
Properties
0.00
Land And Improvements
0.88
Buildings And Improvements
63.75
Machinery Furniture Equipment
72.14
Construction In Progress
49.00
Goodwill And Other Intangible Assets
3.00
Goodwill
1.93
Other Intangible Assets
1.07
Investments And Advances
7.16
Other Non Current Assets
7.43
Total Liabilities Net Minority Interest
721.37
Current Liabilities
104.12
Payables And Accrued Expenses
44.07
Payables
11.14
Accounts Payable
9.58
Current Accrued Expenses
32.93
Total Tax Payable
1.56
Income Tax Payable
1.56
Current Debt And Capital Lease Obligation
20.00
Current Debt
20.00
Other Current Borrowings
20.00
Current Capital Lease Obligation
—
Current Deferred Liabilities
10.51
Current Deferred Revenue
9.09
Other Current Liabilities
28.94
Total Non Current Liabilities Net Minority Interest
617.24
Long Term Debt And Capital Lease Obligation
252.62
Long Term Debt
248.70
Long Term Capital Lease Obligation
3.92
Tradeand Other Payables Non Current
—
Non Current Deferred Liabilities
69.79
Non Current Deferred Revenue
69.79
Other Non Current Liabilities
294.77
Stockholders Equity
-246.17
Common Stock Equity
-246.17
Capital Stock
2.70
Common Stock
2.70
Preferred Stock
0.00
Share Issued
270.03
Ordinary Shares Number
270.03
Treasury Shares Number
0.00
Additional Paid In Capital
2,980.54
Retained Earnings
-3,229.41
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
—
Total Equity Gross Minority Interest
-246.17
Total Capitalization
2.53
Working Capital
269.27
Invested Capital
22.53
Total Debt
272.62
Net Debt
30.22
Capital Lease Obligations
3.92
Net Tangible Assets
-249.17
Tangible Book Value
-249.17
Available For Sale Securities
—
Current Provisions
0.60
Held To Maturity Securities
7.16
Interest Payable
2.15
Investmentin Financial Assets
7.16
Non Current Accrued Expenses
0.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
18.25
-57.06%
42.51
+24.69%
34.09
+142.26%
-80.68
Cash Flow From Continuing Operating Activities
18.25
-57.06%
42.51
+24.69%
34.09
+142.26%
-80.68
Net Income From Continuing Operations
5.86
-78.75%
27.59
+331.09%
-11.94
+86.34%
-87.40
Depreciation Amortization Depletion
12.28
+66.65%
7.37
+62.54%
4.54
-28.15%
6.31
Depreciation
12.28
+66.65%
7.37
+62.54%
4.54
-28.15%
6.31
Depreciation And Amortization
12.28
+66.65%
7.37
+62.54%
4.54
-28.15%
6.31
Other Non Cash Items
4.89
-15.97%
5.82
+320.30%
1.38
-88.45%
11.99
Stock Based Compensation
24.20
+13.28%
21.36
+21.02%
17.65
+31.25%
13.45
Asset Impairment Charge
10.40
+169.70%
3.85
-15.72%
4.57
+107.72%
2.20
Operating Gains Losses
14.16
-21.72%
18.09
+767.07%
2.09
+153.78%
-3.88
Gain Loss On Investment Securities
6.41
+313.48%
1.55
+811.76%
0.17
-81.76%
0.93
Net Foreign Currency Exchange Gain Loss
7.75
+298.34%
-3.91
-303.91%
1.92
+139.83%
-4.81
Gain Loss On Sale Of PPE
—
0.56
0.00
0.00
Change In Working Capital
-50.88
-39.51%
-36.47
-318.02%
16.73
+169.55%
-24.05
Change In Receivables
-4.76
-279.56%
2.65
+13.09%
2.35
+119.86%
-11.81
Changes In Account Receivables
-4.76
-279.56%
2.65
+13.09%
2.35
+119.86%
-11.81
Change In Inventory
-6.62
-107.26%
-3.20
+71.83%
-11.35
-100.12%
-5.67
Change In Prepaid Assets
-10.03
-52.60%
-6.57
+10.17%
-7.32
+52.94%
-15.55
Change In Payables And Accrued Expense
-18.42
-235.53%
-5.49
-206.97%
5.13
+52.18%
3.37
Change In Accrued Expense
3.26
+220.46%
-2.70
-140.92%
6.61
+1013.69%
-0.72
Change In Payable
-21.68
-677.62%
-2.79
-89.27%
-1.47
-135.96%
4.10
Change In Account Payable
-16.71
-499.39%
-2.79
-89.27%
-1.47
-135.96%
4.10
Change In Other Working Capital
-8.26
+46.06%
-15.31
-138.80%
39.46
+179.93%
14.10
Change In Other Current Assets
-1.91
+46.53%
-3.57
-1457.41%
0.26
-49.71%
0.52
Change In Other Current Liabilities
-0.87
+82.48%
-4.98
+57.81%
-11.81
-30.95%
-9.02
Investing Cash Flow
-304.80
-215.37%
-96.65
-4761.62%
-1.99
-140.79%
4.87
Cash Flow From Continuing Investing Activities
-304.80
-215.37%
-96.65
-4761.62%
-1.99
-140.79%
4.87
Net PPE Purchase And Sale
-4.57
+52.89%
-9.69
+77.16%
-42.44
-459.24%
-7.59
Purchase Of PPE
-4.57
+52.89%
-9.69
+77.16%
-42.44
-459.24%
-7.59
Capital Expenditure
-4.57
+52.89%
-9.69
+77.16%
-42.44
-459.24%
-7.59
Net Investment Purchase And Sale
57.51
+166.13%
-86.96
-314.96%
40.45
+45.49%
27.80
Purchase Of Investment
-157.80
+43.80%
-280.80
-255.01%
-79.09
+0.55%
-79.54
Sale Of Investment
215.31
+11.08%
193.84
+62.14%
119.55
+11.37%
107.34
Net Business Purchase And Sale
-347.74
0.00
0.00
+100.00%
-15.34
Purchase Of Business
-347.74
0.00
0.00
+100.00%
-15.34
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Net Other Investing Changes
-10.00
-2625.25%
0.40
+3.66%
0.38
—
Financing Cash Flow
315.10
+329.55%
-137.27
-200.48%
136.61
+538.71%
21.39
Cash Flow From Continuing Financing Activities
315.10
+329.55%
-137.27
-200.48%
136.61
+538.71%
21.39
Net Issuance Payments Of Debt
325.00
+344.05%
-133.17
-1897.42%
-6.67
0.00
Issuance Of Debt
325.00
0.00
0.00
0.00
Repayment Of Debt
0.00
+100.00%
-133.17
-1897.42%
-6.67
0.00
Long Term Debt Issuance
325.00
0.00
0.00
0.00
Long Term Debt Payments
0.00
+100.00%
-133.17
-1897.42%
-6.67
0.00
Net Long Term Debt Issuance
325.00
+344.05%
-133.17
-1897.42%
-6.67
0.00
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
0.00
-100.00%
6.89
-65.20%
19.79
Proceeds From Stock Option Exercised
1.99
-36.54%
3.14
+72.47%
1.82
-34.20%
2.77
Net Other Financing Charges
-11.89
-64.34%
-7.24
-105.38%
134.57
+11621.15%
-1.17
Changes In Cash
28.55
+114.92%
-191.40
-213.45%
168.71
+410.04%
-54.42
Beginning Cash Position
47.08
-80.26%
238.48
+241.82%
69.77
-43.82%
124.18
End Cash Position
75.63
+60.65%
47.08
-80.26%
238.48
+241.82%
69.77
Free Cash Flow
13.69
-58.29%
32.82
+493.17%
-8.35
+90.54%
-88.27
Interest Paid Supplemental Data
14.72
-15.94%
17.51
-4.23%
18.28
+106.50%
8.85
Income Tax Paid Supplemental Data
1.71
-60.00%
4.26
0.00
—
Amortization Of Securities
-2.65
+48.02%
-5.09
-450.49%
-0.93
-230.83%
0.71
Change In Income Tax Payable
-4.97
0.00
0.00
—
Change In Interest Payable
—
—
0.00
0.00
Change In Tax Payable
-4.97
0.00
0.00
—
Common Stock Issuance
0.00
0.00
-100.00%
6.89
-65.20%
19.79
Issuance Of Capital Stock
0.00
0.00
-100.00%
6.89
-65.20%
19.79
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category